NVH-020B is under clinical development by NVH Medicinal and currently in Phase I for Hemorrhage. According to GlobalData, Phase I drugs for Hemorrhage have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NVH-020B’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NVH-020B overview
NVH-020B is under development for the treatment of hemorrhages and severe bleeding disorders. It is administered by the parenteral route. It is a collagen like recombinant protein.
NVH Medicinal overview
NVH Medicinal is a developer of genetically engineered protein products. The company’s product includes NVH-020, a recombinant collagen-like protein that offers biomedical applications in homeostasis and tissue engineering. It’s product is used as hemostat in medical devices as a biologic scaffold for constructive tissue, as an inducer of endogenous tissue regeneration and as an adhesive protein for engineered stem cell niches. NVH Medicinal develops product for treatment of hemorrhage, diabetic ulcer, and willebrand diseases. The company provides customized research services such as protein and antibody engineering, and preclinical efficacy, among others. NVH Medicinal is headquartered in Dijon, France.
For a complete picture of NVH-020B’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
